10 completed, 1 active not recruiting, 1 no longer available, 1 terminated. 7 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 2 | 7 | Completed 5, Active not recruiting 1, Terminated 1 |
Follow Cognition Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease CT1812, Placebo - Early Alzheimer's Disease | Phase 2 | Active not recruiting | Cognition Therapeutics | 540 | 2023-06-28 | 2026-08-10 |
| Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD). Active Comparator CT1812, Placebo Comparator - Age-Related Macular Degeneration | Phase 2 | Terminated | Cognition Therapeutics | 100 | 2023-06-16 | 2025-04-16 |
| Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies CT1812 - Dementia With Lewy Bodies | Phase 2 | Completed | Cognition Therapeutics | 130 | 2022-05-19 | 2026-03-12 |
| Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers CT1812 - Alzheimer Disease | Phase 1 | Completed | Cognition Therapeutics | 35 | 2022-02-15 | 2023-04-12 |
| Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects 300 mg [C14] CT1812 - Alzheimer Disease | Phase 1 | Completed | Cognition Therapeutics | 8 | 2021-12-31 | 2023-07-21 |
| Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG CT1812, Placebo - Alzheimer Disease | Phase 2 | Completed | Cognition Therapeutics | 16 | 2020-07-09 | 2024-11-29 |
| A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease. CT1812, Placebo - Mild to Moderate Alzheimer's Disease | Phase 2 | Completed | Cognition Therapeutics | 153 | 2018-10-10 | 2025-08-11 |
| Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease CT1812, Placebo - Alzheimer Disease | Phase 1 | Completed | Cognition Therapeutics | 3 | 2018-05-30 | 2022-01-12 |
| Effect of CT1812 Treatment on Brain Synaptic Density Active Treatment- CT1812 100 mg, Active Treatment- CT1812 300 mg, Placebo - Alzheimer Disease | Phase 1 / Phase 2 | Completed | Cognition Therapeutics | 43 | 2018-03-28 | 2023-09-07 |
| Drug Interaction Study of CT1812 in Healthy Volunteers CT1812, tolbutamide, dextromethorphan - Healthy Volunteers | Phase 1 | Completed | Cognition Therapeutics | 16 | 2016-11-10 | 2018-10-23 |
| Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease CT1812, Placebo - Alzheimer's Disease | Phase 1 / Phase 2 | Completed | Cognition Therapeutics | 19 | 2016-09-01 | 2018-07-26 |
| Ascending Dose Study of CT1812 in Healthy Volunteers CT1812, Placebo - Cognitive Impairment | Phase 1 | Completed | Cognition Therapeutics | 80 | 2015-09-01 | 2016-09-07 |
| Expanded Access Program for CT1812 (Zervimesine) zervimesine - Dementia With Lewy Bodies | No longer available | Cognition Therapeutics | 2026-05-28 |
Alzheimer Disease (9) · Dementia (2) · Lewy Body Disease (2) · Cognitive Dysfunction (1) · Macular Degeneration (1)
Drug Evaluation (4) · Carbon-14 (1) · Dextromethorphan (1) · Midazolam (1) · Omeprazole (1) · Tolbutamide (1)
United States (10) · Australia (3) · Netherlands (2) · Czechia (1) · Spain (1)
Anthony Caggiano, MD (5) · Alyssa Galley (2) · Anthony Caggiano (1) · Anthony Caggiano, PHD (1) · Christopher van Dyck, MD (1) · Everard Vijverberg, MD (1) · Jason Lickliter, MD (1) · Michael Woodward, MD (1)
PMID 39166791, PMID 33559354, PMID 37173791, PMID 38273408, PMID 38914170, PMID 39559892, PMID 41416579, PMID 41747884, PMID 41930592, PMID 41943055
2019 (1), R01AG058660 (1), R01AG065248 (1), R01AG071643 (1), RF1AG057553 (1), RF1AG058710 (1), SB1AG073028 (1)